Michael Morabito
Stock Analyst at Chardan Capital
(n/a)
# 4,371
Out of 4,831 analysts
11
Total ratings
9.09%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Morabito
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $79 → $81 | $40.01 | +102.45% | 2 | Mar 17, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $202 → $203 | $295.36 | -31.27% | 2 | Feb 26, 2021 | |
| DRRX DURECT | Maintains: Buy | $70 → $80 | $0.66 | +12,039.61% | 2 | Feb 3, 2021 | |
| ETNB 89bio | Maintains: Buy | $59 → $95 | $7.80 | +1,117.95% | 3 | Sep 15, 2020 | |
| VKTX Viking Therapeutics | Maintains: Buy | $15 → $20 | $27.74 | -27.89% | 2 | Aug 31, 2020 |
Akero Therapeutics
Mar 17, 2021
Maintains: Buy
Price Target: $79 → $81
Current: $40.01
Upside: +102.45%
Madrigal Pharmaceuticals
Feb 26, 2021
Maintains: Buy
Price Target: $202 → $203
Current: $295.36
Upside: -31.27%
DURECT
Feb 3, 2021
Maintains: Buy
Price Target: $70 → $80
Current: $0.66
Upside: +12,039.61%
89bio
Sep 15, 2020
Maintains: Buy
Price Target: $59 → $95
Current: $7.80
Upside: +1,117.95%
Viking Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: $15 → $20
Current: $27.74
Upside: -27.89%